JP2023523600A - ヒトプログラム細胞死リガンド1(pd-l1)を標的とする単一可変ドメイン抗体およびその誘導体 - Google Patents
ヒトプログラム細胞死リガンド1(pd-l1)を標的とする単一可変ドメイン抗体およびその誘導体 Download PDFInfo
- Publication number
- JP2023523600A JP2023523600A JP2022564470A JP2022564470A JP2023523600A JP 2023523600 A JP2023523600 A JP 2023523600A JP 2022564470 A JP2022564470 A JP 2022564470A JP 2022564470 A JP2022564470 A JP 2022564470A JP 2023523600 A JP2023523600 A JP 2023523600A
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- single variable
- antibody
- domain antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010324761.8 | 2020-04-22 | ||
| CN202010324761 | 2020-04-22 | ||
| PCT/CN2021/088674 WO2021213435A1 (zh) | 2020-04-22 | 2021-04-21 | 一种靶向人程序性死亡配体1(pd-l1)的单可变域抗体及其衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523600A true JP2023523600A (ja) | 2023-06-06 |
| JP2023523600A5 JP2023523600A5 (cg-RX-API-DMAC7.html) | 2024-05-01 |
Family
ID=78095333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022564470A Pending JP2023523600A (ja) | 2020-04-22 | 2021-04-21 | ヒトプログラム細胞死リガンド1(pd-l1)を標的とする単一可変ドメイン抗体およびその誘導体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230279115A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4144758A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023523600A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113527488B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021213435A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022268168A1 (zh) * | 2021-06-23 | 2022-12-29 | 迈威(上海)生物科技股份有限公司 | 靶向lag-3和pd-l1的新型双特异抗体及其应用 |
| CN113940997B (zh) * | 2021-12-21 | 2022-04-08 | 迈威(上海)生物科技股份有限公司 | 一种双特异性抗体的稳定制剂 |
| CN115925947B (zh) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟 |
| CN120380023A (zh) * | 2022-10-20 | 2025-07-25 | 基础应用医学研究基金会 | 用于癌症治疗的纳米抗体 |
| CN117660358B (zh) * | 2024-01-31 | 2024-05-14 | 青岛华赛伯曼医学细胞生物有限公司 | 表达分泌型融合蛋白的工程化免疫细胞及其应用 |
| WO2025242206A1 (zh) * | 2024-05-24 | 2025-11-27 | 苏州康宁杰瑞生物科技有限公司 | 基于pd-l1结合多肽的多功能分子 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018529375A (ja) * | 2015-07-31 | 2018-10-11 | スジョウ・アルファマブ・カンパニー・リミテッドSuzhou Alphamab Co.,Ltd. | プログラム死リガンド(pdl1)に対する単一ドメイン抗体およびその誘導体タンパク質 |
| EP3444277A1 (en) * | 2016-03-18 | 2019-02-20 | Suzhou Nanomab Technology Limited | Anti-pd-l1 nanobody, coding sequence and use thereof |
| WO2019096121A1 (en) * | 2017-11-17 | 2019-05-23 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-l1 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ATE374248T1 (de) | 1996-06-27 | 2007-10-15 | Vlaams Interuniv Inst Biotech | Antikörpermoleküle, die spezifisch mit dem aktiven zentrum oder dem aktiven spalt eines zielmoleküls interagieren |
| AU3596599A (en) | 1998-01-26 | 1999-08-09 | Unilever Plc | Method for producing antibody fragments |
| BR9916765A (pt) | 1999-01-05 | 2001-09-25 | Unilever Nv | Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico |
| ATE276359T1 (de) | 1999-01-19 | 2004-10-15 | Unilever Nv | Verfahren zur herstellung von antikörperfragmenten |
| CN1252264C (zh) | 1999-04-22 | 2006-04-19 | 荷兰联合利华有限公司 | 利用单价抗原-结合蛋白抑制病毒感染 |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| ATE440111T1 (de) | 1999-11-29 | 2009-09-15 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
| ATE342922T1 (de) | 1999-11-29 | 2006-11-15 | Unilever Nv | Immobilisierung von proteinen mit hilfe eines polypeptidsegments |
| ATE428733T1 (de) | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
| US20030190598A1 (en) | 2000-05-26 | 2003-10-09 | Jasmid Tanha | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| AU2002229639A1 (en) | 2000-12-13 | 2002-06-24 | De Haard, Johannes Joseph Wilhelmus | Camelidae antibody arrays |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| JP4323317B2 (ja) | 2001-12-21 | 2009-09-02 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー(ヴェーイーベー・ヴェーゼットウェー) | 可変領域配列のクローニング方法 |
| WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558645B1 (en) | 2002-11-08 | 2011-07-27 | Ablynx N.V. | Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation |
| US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
| JP2007521234A (ja) | 2003-08-12 | 2007-08-02 | ウィリアム エム ヤーブロー | 尋常性ざ瘡の治療薬及び使用方法 |
| PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| MX2007006593A (es) | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| JP2008528010A (ja) | 2005-01-31 | 2008-07-31 | アブリンクス ナームローゼ フェンノートシャップ | 重鎖抗体の可変ドメイン配列を作出する方法 |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| LT2444424T (lt) | 2005-05-20 | 2018-10-25 | Ablynx N.V. | Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui |
| BRPI0710572A2 (pt) | 2006-01-24 | 2013-01-08 | Domantis Limited | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| CN101663319A (zh) | 2007-02-21 | 2010-03-03 | 埃博灵克斯股份有限公司 | 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病 |
| MX2009012650A (es) | 2007-05-24 | 2010-02-18 | Ablynx Nv | Secuencias de aminoacido dirigidas contra rank-l y polipeptidos que comprenden lo mismo para el tratamiento de enfermedades y trastornos de huesos. |
| WO2016197367A1 (en) * | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| CN107400166A (zh) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
| CN109485726B (zh) * | 2017-09-13 | 2022-07-08 | 和迈生物科技有限公司 | 放射性标记抗纳米抗体在癌症的预后、诊断中的应用 |
| CN110144010B9 (zh) * | 2018-02-14 | 2021-01-05 | 上海洛启生物医药技术有限公司 | 阻断型pd-l1驼源单域抗体及其用途 |
| CN109265548B (zh) * | 2018-09-13 | 2021-05-18 | 东南大学 | 抗pd-l1纳米抗体及其编码序列、制备方法和应用 |
| CN110627904B (zh) * | 2019-10-31 | 2020-07-10 | 南京蓝盾生物科技有限公司 | 抗人gpc3单克隆抗体 |
| EP4194002A4 (en) * | 2020-07-24 | 2024-08-14 | Mabwell (Shanghai) Bioscience Co., Ltd. | TGF-BETA RII MUTANT AND ASSOCIATED FUSION PROTEIN |
-
2021
- 2021-04-21 EP EP21793484.3A patent/EP4144758A4/en not_active Withdrawn
- 2021-04-21 US US17/996,802 patent/US20230279115A1/en not_active Abandoned
- 2021-04-21 JP JP2022564470A patent/JP2023523600A/ja active Pending
- 2021-04-21 CN CN202110433149.9A patent/CN113527488B/zh active Active
- 2021-04-21 WO PCT/CN2021/088674 patent/WO2021213435A1/zh not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018529375A (ja) * | 2015-07-31 | 2018-10-11 | スジョウ・アルファマブ・カンパニー・リミテッドSuzhou Alphamab Co.,Ltd. | プログラム死リガンド(pdl1)に対する単一ドメイン抗体およびその誘導体タンパク質 |
| EP3444277A1 (en) * | 2016-03-18 | 2019-02-20 | Suzhou Nanomab Technology Limited | Anti-pd-l1 nanobody, coding sequence and use thereof |
| WO2019096121A1 (en) * | 2017-11-17 | 2019-05-23 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-l1 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113527488B (zh) | 2026-04-17 |
| EP4144758A4 (en) | 2024-05-15 |
| US20230279115A1 (en) | 2023-09-07 |
| EP4144758A1 (en) | 2023-03-08 |
| CN113527488A (zh) | 2021-10-22 |
| WO2021213435A1 (zh) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11912770B2 (en) | Blocking type PD-L1 single-domain camel antibody and application thereof | |
| EP4144758A1 (en) | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof | |
| JP2022106751A (ja) | GUCY2cに特異的な抗体及びその使用 | |
| US11359021B2 (en) | PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| EP4289862A1 (en) | Anti-human b7-h3 antibody and application thereof | |
| JP7711208B2 (ja) | Dll3に対する結合分子及びその使用 | |
| EP3712170A1 (en) | Cd96 antibody, antigen-binding fragment and pharmaceutical use thereof | |
| CN111499750B (zh) | 一种抗癌胚抗原的高中和活性纳米抗体及其应用 | |
| CN114262377B (zh) | 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列 | |
| CN106946989B (zh) | 抗cea抗原vhh结构域及含有其的双特异性抗体 | |
| CN111196854A (zh) | Ox40抗体及其制备方法和应用 | |
| US20250043015A1 (en) | Anti-tnfr2 single domain antibody, and preparation method therefor and application thereof | |
| CN105820250A (zh) | 一种抗basigin人源化抗体及其应用 | |
| CN110642951A (zh) | 一种抗ca125糖类抗原的高中和活性纳米抗体及其应用 | |
| KR20250173509A (ko) | 클라우딘18.2에 특이적으로 결합하는 항체, 및 이의 제조 방법 및 이의 응용 | |
| CN112480250B (zh) | 一种抗人骨桥蛋白的抗体及其应用 | |
| US12435135B2 (en) | Human CD47-targeting single-domain antibody and use thereof | |
| CN115109154A (zh) | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 | |
| CN113754770B (zh) | 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒 | |
| CN112851815B (zh) | 抗bcma抗体或其抗原结合片段及其制备方法和应用 | |
| CN116023492B (zh) | 一种阻断pd1与pdl1结合的抗人pdl1纳米抗体的制备方法及其编码序列 | |
| CN119591709A (zh) | 一种抗cd25抗体及其应用 | |
| JP2025531938A (ja) | 抗4-1bbナノボディ、その製造及び使用 | |
| CN121293358A (zh) | 结合EpCAM的纳米抗体、嵌合抗原受体及其应用 | |
| CN121609799A (zh) | 一种抗pd-l1的纳米抗体、含其的双特异性重组蛋白及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240419 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240419 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250311 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250829 |